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Abstract
Background: The pancreas is a rare location for metastatic disease, with only 2–11% of all pancreatic
tumours being of non-primary origin. It is also uncommon for renal cell carcinoma (RCC) to metastasize
to the pancreas (1–3% of cases) and, when it does, it typically occurs substantially after index nephre-
ctomy. It is not known whether all pancreatic metastases need be resected because today's chemo- and
biological therapies are increasingly effective in controlling advanced disease.
Methods: Six patients with a variety of symptoms are discussed. Four patients presented with recurrent
gastrointestinal bleeding, ranging from occult to life-threatening in severity.
Results: The four patients with gastrointestinal bleeding had RCC metastases that had eroded into the
duodenum and were successfully controlled by palliative pancreaticoduodenectomy or completion pan-
createctomy. The other two patients were treated using different chemotherapeutic or biological agents.
Conclusions: Renal cell carcinoma metastases to the pancreas typically occur long after index nephre-
ctomy. Although clinical presentation is variable, palliative resection should be reserved for those who
develop complications, such as upper gastrointestinal bleeding, and, in other series, obstructive jaundice.
Routine debulking resections do not appear to be indicated because current biological therapies effec-
tively and reliably control disease over long periods.
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Introduction
Metastases to the pancreas are rare, comprising only 2–11% of
malignancies involving the organ.1 Of resected pancreatic
tumours, 0.25–3.00% of specimens are pathologically determined
to be renal cell carcinoma (RCC), depending on the series.2,3 There
is often a prolonged interval between the resection of the primary
renal tumour and the subsequent appearance of pancreatic
metastases, with reported median periods of 7–10 years,2,3 and as
long as 23 years in one case.3 Symptoms of pancreatic involvement
are variable, ranging from none (incidental abdominal imaging
findings) to abdominal pain, evidence of biliary obstruction, vom-
iting, anaemia, weight loss, new-onset diabetes and upper gas-
trointestinal (UGI) bleeding.2–5
In the absence of systemic disease or major co-morbidities,
pancreatic resection has become an accepted treatment modality
for such patients, as well as for other non-pancreatic primary
tumours, such as malignant fibrous histiocytoma, and pancreati-
coduodenectomy, distal pancreatectomy and total pancreatec-
tomy have all been performed to this end.1,4,6 In fact, recently,
pancreatic resection has gained acceptance for treatment of iso-
lated metastases with manageable systemic burden.6–8
We present a contemporary series of six patients with meta-
static RCC to the pancreas referred for surgical evaluation at our
institution. Ultimately, four of these patients required pancreatic
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resection; however, the other two were managed with solely
medical therapy. It is important to note that each of the patients
undergoing resection required emergency or semi-emergency sur-
gical intervention for tumour-related haemorrhage. In describing
this series of patients, we propose that not all pancreatic
metastases of renal cell origin need to be aggressively resected.
Given the efficacy of emerging chemo- and biological therapies
currently applied for advanced disease, radical surgical resections
may best be withheld.
Materials and methods
Overview
This series of patients was drawn from a 10-year period at a
multidisciplinary, tertiary care medical centre with both a high-
volume specialty practice in hepato-pancreato-biliary surgery and
a busy medical oncology practice with a strong focus on RCC. The
median time for appearance of metastatic disease following resec-
tion of the primary tumour in this series was just under 10 years
(range 0–19 years). Consistent with other published reports, the
median age of patients in this series at the time of discovery of
pancreatic involvement was 69 years.3
Specific patient characteristics and results, accrued from chart
review, are summarized below. Our series reflected a broad range
of presenting ailments. Our subjects included asymptomatic
patients, whose disease was discovered by radiographic surveil-
lance, and patients with physical symptoms, such as pain, fatigue,
jaundice and upper or lower gastrointestinal bleeding.
History and presentation
Patient 1
A 69-year-old woman presented with a left parotid mass. This
proved to be a synchronous metastasis from a right RCC. Follow-
ing simultaneous parotid and renal resections carried out after
presentation, she remained in good health for 9 years until a
computed tomography (CT) scan performed for right lower
quadrant discomfort revealed pancreatic lesions typical in appear-
ance of metastatic RCC (Fig. 1).
Patient 2
A 68-year-old man underwent a right radical nephrectomy for
RCC in 1989. He maintained good health for 15 years until late
2004, when he developed fatigue and began passing melena.
Evaluation with axial imaging led to the discovery of two masses
in the head of the pancreas (Fig. 2).
Patient 3
A 48-year-old woman was diagnosed with RCC in 1995 and
underwent right radical nephrectomy at the time. She was subse-
quently treated with interleukin-2 (IL-2) for concurrent meta-
static ovarian disease. She was well for 5 years, until a surveillance
CT scan revealed a 2 ¥ 3-cm lesion in the tail of the pancreas, and
a distal pancreatectomy and splenectomy were performed. These
were followed by induction of adjuvant biological therapy using
IL-12 and Bayer 43-9006. Later CT scans showed lesions in the
liver, as well as a progressively enlarging lesion in the head of the
pancreas.
Patient 4
A 75-year-old man with a remote history of RCC, who was asymp-
tomatic, was found incidentally to have a pancreatic mass during
a screening CT scan. Repeat imaging showed multiple hypervas-
cular pancreatic lesions, which, on the basis of the subject’s pre-
vious right nephrectomy for RCC 19 years earlier, was concluded
to be consistent with multifocal metastatic RCC (subsequently
proven by biopsy).
Patient 5
Eleven years after an index nephrectomy for RCC, a 67-year-
old man presented with a small ampullary lesion identified by
Figure 1 Computed tomography scan showing a large pancreatic
lesion typical in appearance of metastatic renal cell carcinoma
(patient 1)
Figure 2 Coronal section of a computed tomography scan showing
two masses in the head of the pancreas (patient 2)
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endoscopy carried out for occult UGI bleeding. Imaging studies
revealed diffuse metastatic involvement of the pancreas.
Patient 6
An 87-year-old, otherwise healthy woman presented initially
with jaundice and abdominal pain. She was found to have syn-
chronous masses in the pancreas and left kidney, which were
proven to be RCC of clear cell type upon endoscopic




One patient in this series underwent an elective surgical procedure
as the initial step once metastatic disease to the pancreas became
apparent. A distal pancreatectomy and splenectomy were per-
formed in patient 3 when a CT scan detected metastatic disease in
the pancreas. She did, however, develop recurrent disease shortly
thereafter.
Urgent pancreatic resection
Three patients required semi-urgent or urgent pancreati-
coduodenectomy. In all these cases this resulted from tumour
erosion through the wall of the duodenum, leading to haemody-
namically significant, transfusion-dependent UGI bleeding.
Patient 1 was admitted for UGI bleeding with a drop in haema-
tocrit to 18.9. An emergency Whipple procedure for uncontrolled
duodenal bleeding was performed and it was discovered intraop-
eratively that a 5-cm mass had eroded through the wall of the first
and second portions of the duodenum. Pathological analysis dem-
onstrated a 6.7-cm metastatic RCC of clear cell type, involving
both the duodenum and the pancreas.
Patient 2 presented to a referring hospital with significant UGI
bleeding that required transfusion. Esophagogastroduodenoscopy
(EGD) showed a 10-mm ulcer in the second portion of the duode-
num. The bleeding could not be controlled and the patient was
transferred to our institution, where he underwent an emergency
Whipple resection.
Over time, patient 3, whose initial metastatic disease had
been managed operatively (see above: distal pancreatectomy/
splenectomy), developed increasing fatigue, shortness of breath
and black stools, prompting an EGD. A friable and actively bleed-
ing mass was seen in the third portion of the duodenum, which
could not be controlled endoscopically and led to a significant
drop in haematocrit despite multiple transfusions. The decision
was made to proceed with a completion pancreatectomy (pylorus-
preserving). Pathology later showed metastatic RCC to the head of
the pancreas, which had eroded through the duodenal wall.
No pancreatic resection
Because of the multifocal nature of patient 4’s disease, in conjunc-
tion with his lack of symptoms, it was decided that it would be
imprudent to proceed with a radical pancreatic resection or total
pancreatectomy. High-dose IL-2 was not considered a possibility
secondary to the patient’s co-morbidities, but it was thought that
he might do well on Sorafenib.
Patient 5 underwent an exploratory laparotomy, which
showed widespread metastatic involvement of the pancreas. It
was decided at the time not to perform a total pancreatectomy.
The patient was initially started on the epidermal growth factor
receptor inhibitor cetuximab (ABX-EGF), but was switched to
IL-2 secondary to disease progression. The disease remained
stable for some time until a second bout of UGI bleeding led to
the discovery of an infra-ampullary duodenal mass, which was
resected because of resultant bleeding and perforation. The
patient recovered nicely and was started on Avastin for control
of his disease.
Patient 6 was not interested in operative interventions at
the age of 87 years. She therefore underwent endoscopic
management of her biliary obstruction, which proved to be sec-
ondary to a metastatic pancreatic lesion discovered at the same
time.
Discussion
Renal cell carcinoma has long been notorious for its lack of
response to conventional chemoradiotherapy, with response rates
typically in the range of 4–6%.9 Compounding this problem is the
apparent rise in incidence of this cancer, which is reported to be as
much as 126% over the past 50 years.10 Although any metastatic
disease to the pancreas is rare, when it does occur, a renal cell
primary has long been recognized as a potential culprit.8 The
dually fascinating and confounding hallmark of this disease entity
is the degree of latency between the identification and resection of
the primary tumour, and the diagnosis of a pancreatic metastasis,
between which there is a median time interval of 7–10 years.2,3,8 By
comparison, it is far less common to have synchronous metastatic
disease: one meta-analysis places the incidence of synchronous
disease at 12%.8
The management of metastatic RCC to the pancreas has
become, by consensus, largely surgical. Multiple case reports, case
series and meta-analyses suggest that aggressive surgical resection
confers a significant survival advantage in this situation.4,7,8,11,12
Law et al. found that 11 of 14 patients who underwent pancreatic
resection were alive at 32 months of follow-up, although only
seven of them were disease-free.7 It is important to note, however,
that five patients were operated for reasons secondary to symp-
toms of their disease, not as a matter of protocol. The authors
noted that proving a survival benefit in asymptomatic patients
would be a difficult task.7
As previously mentioned, until recently, results of traditional
chemoradiotherapy in this disease have been abysmal.9,10 The
immunomodulators interferon-alpha (IFN-a) and IL-2 have been
in use for some time, and the current standard in the treatment of
metastatic disease is IL-2.9 These drugs have now been used in
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combination, and at low doses, to successfully control widespread
disease,13 suggesting a synergistic effect that also avoids the
toxicity associated with high-dose IFN-a. Better understanding of
RCC and its biology has led to multiple new targeted therapies,
which are in varying states of study and/or clinical use.14
Hainsworth et al. published results from a series of 63 patients
with metastatic RCC treated using the vascular endothelial growth
factor (VEGF) inhibitor bevacizumab and the tyrosine kinase
inhibitor erlotinib. Their data showed that disease either regressed
or stabilized in 86% of patients receiving this therapy.15 Another
study of 63 patients treated with a small molecule inhibitor of the
VEGF and platelet-derived growth factor (PDGF) receptors,
sunitib malate (SU11248), demonstrated a 67% rate of response
or disease stabilization.16
Given the successes achieved using some of these new biologi-
cal therapeutic agents, and the relatively indolent behaviour of
RCC metastatic to the pancreas, it may be relevant to revisit
current treatment recommendations. A distinction must be
made between isolated pancreatic metastases and widespread
RCC. The biology of this tumour naturally blurs this distinction
and the certainty with which one can judge a metastatic deposit
in the pancreas to be representative of truly isolated disease is
suspect. In their series of 23 patients, Zerbi et al. noted a 34.8%
rate of multifocal pancreatic metastases by pathological exami-
nation, but preoperative imaging had predicted multiple lesions
far less often.17 As most of these series are small and their
follow-up generally limited, their power must also be ques-
tioned. In addition, some distinction must be made between the
management of symptomatic and asymptomatic patients. It is
difficult to argue that pancreatic resection should not be
undertaken (if possible) in symptomatic patients, especially in
cases of bleeding or obstruction, as it is also difficult to prove
unambiguous survival benefit in those with asymptomatic
disease.7,18
Conclusions
Renal cell carcinoma metastases to the pancreas typically occur
long after index nephrectomy. Given the heterogeneity of RCC
biology and the difficulty of accurately identifying the full extent
of disease spread preoperatively,17 palliative resection should be
reserved for those who develop complications such as UGI bleed-
ing and, in other series, obstructive jaundice. Routine or radical
debulking resections do not appear to be indicated as today’s new
biological therapies effectively and reliably control disease over
long periods. Although the morbidity of major pancreatic resec-
tion is quite low, especially in high-volume centres, postoperative
quality of life must be compared with quality of life achieved by
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